Viome is a microbiome startup designed to help people track their health. Viome takes a comprehensive approach to analyze and decode an individual’s microbiome, providing them with valuable insights tailored to their unique biology. Their advanced technology combines metatranscriptomics, artificial intelligence, and machine learning algorithms to analyze the RNA molecules produced by the microorganisms in our gut.
Viomehas raised $86.5 million in a Series C round to expand its business. The new round was led by Khosla Ventures and Bold Capital, with other unnamed existing and new investors also participating.
Viome, Bellevue, Washington, United States, was founded in 2016 by Naveen Jain. Viome has run tests for some 350,000 consumers from 106 countries (primarily the US, UK, Canada and Australia) till that moment, working out to some 600,000 samples that are feeding and informing its algorithm. “We made the strategic decision to invest in Viome, recognizing the groundbreaking fusion of its one-of-a-kind RNA technology with state-of-the-art AI,” Robbie Schwietzer, a partner at Khosla Ventures, said in a statement. “Coupled with an unparalleled repository of biological data, this synergy doesn’t just hint at a revolution; it marks the dawn of a new era in healthcare.”
